Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Organisation › Details

Dicerna Pharmaceuticals Inc. (Nasdaq: DRNA)

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. *


Period Start 2007-11-01 established
Products Industry RNAi drug (RNAi therapeutic)
  Industry 2 GalXC™ RNAi technology platform
Person Person Fambrough, Douglas M. (Dicerna Pharmaceuticals 201711 CEO)
Region Region Cambridge, MA
  Country United States (USA)
  Street 87 Cambridgepark Drive
  City 02140 Cambridge, MA
  Tel +1-617-621-8097
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Boehringer Ingelheim. (11/2/17). "Press Release: Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)". Ingelheim & Cambridge, MA.
Record changed: 2019-11-27


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Dicerna Pharmaceuticals Inc. (Nasdaq: DRNA)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top